New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 14, 2012
07:31 EDTACRXAcelRx announces top-line data from Phase 3 study of Sufentanil NanoTab
AcelRx Pharmaceuticals announced top-line data from its previously announced open-label, active-comparator study of its lead product candidate, the Sufentanil NanoTab PCA System. Top-line results of the Phase 3 clinical trial demonstrate that the Sufentanil NanoTab PCA System was non-inferior to intravenous patient-controlled analgesia with morphine for the primary endpoint of Patient Global Assessment of method of pain control over the 48-hour study period as determined by the combined percentage of patients with PGA ratings of "good" or "excellent".
News For ACRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 13, 2014
07:08 EDTACRXAcelRx to present positive efficacy results in Phase 3 trial of Zalviso
AcelRx Pharmaceuticals will present safety and efficacy data from a Phase 3 pivotal trial evaluating the Zalviso sufentanil sublingual tablet system for the treatment of moderate-to-severe acute pain following joint replacement surgery at the American Society of Regional Anesthesia and Pain Medicine 13th Annual Pain Medicine Meeting on November 13th to November 16th in San Francisco. Data from the sublingual sufentanil tablet system development program highlights efficacy across various demographic populations

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use